Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398818 | 1.00 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2NR1H3PIK3CA | |
| SCHEMBL2386023 | 1.00 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2NR1H3PIK3CA | |
| SCHEMBL21224528 | 0.88 | USP2 (0.41) | NR1H2USP2SMN1; SMN2NR1H3RECQL | |
| SCHEMBL21682785 | 0.88 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2NR1H3RECQL | |
| SCHEMBL13749174 | 0.87 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2NR1H3GPR119 | |
| SCHEMBL14829403 | 0.87 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2NR1H3GPR119 | |
| SCHEMBL14829637 | 0.87 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2NR1H3GPR119 | |
| SCHEMBL18394698 | 0.86 | NPC1 (0.47) | NR1H2USP2SMN1; SMN2NR1H3RECQL | |
| SCHEMBL14916072 | 0.86 | CFB (0.42) | NR1H2USP2SMN1; SMN2NR1H3RECQL | |
| SCHEMBL29529079 | 0.86 | USP2 (0.40) | NR1H2USP2SMN1; SMN2NR1H3RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| CN-1665789-A | Diaminopyrimidinecarboxa mide derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | NR1H2 3709/4885USP2 3005/4885SMN1; SMN2 4649/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | NR1H2 3380/4885USP2 3936/4885SMN1; SMN2 4496/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | NR1H2 3709/4885USP2 3005/4885SMN1; SMN2 4649/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | NR1H2 3187/4885USP2 4335/4885SMN1; SMN2 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.